Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation. (2018)

• Record Type: Journal Article
• Authors: Caocci, Giovanni; Atzeni, Sandra; Usai, Monica; La Nasa, Giorgio
• Is Part Of: Leukemia research reports. Volume 9(2018)
• Page Start: 14
• Page End: 15
• Publication Date: 2018
• Subjects: Essential thrombocytemia -- Immune thrombocytopenia -- JAK2V617F mutation; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2017.12.002
• Languages: English
• ISSNs: 2213-0489

Abstract

Abstract: JAK2 V617F mutation is found in about 60% of cases of essential thrombocytemia (ET) and represents a driving mutation. Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet (PLT) count. So far, only 2 reports described ET following ITP. For the first time we analyzed in a patient the JAK2 V617F allele burden at ITP onset occurred 13 years before the ET diagnosis and found the presence of a small clone JAK2 V617F positive clone (3%) raised to 27% in the following years. The association of ET and ITP could suggest similar pathogenetic mechanisms that should be further investigated.